LRI Investments LLC Makes New $322,000 Investment in Sanofi (NASDAQ:SNY)

LRI Investments LLC purchased a new position in Sanofi (NASDAQ:SNY) in the 1st quarter, Holdings Channel reports. The firm purchased 6,411 shares of the company’s stock, valued at approximately $322,000.

Several other hedge funds have also recently modified their holdings of SNY. HB Wealth Management LLC increased its position in Sanofi by 7.3% during the fourth quarter. HB Wealth Management LLC now owns 4,327 shares of the company’s stock valued at $215,000 after acquiring an additional 293 shares during the last quarter. Schechter Investment Advisors LLC increased its position in Sanofi by 6.1% during the fourth quarter. Schechter Investment Advisors LLC now owns 45,256 shares of the company’s stock valued at $2,251,000 after acquiring an additional 2,593 shares during the last quarter. Planned Solutions Inc. purchased a new stake in Sanofi during the fourth quarter valued at $183,000. Great Lakes Retirement Inc. increased its position in Sanofi by 1.6% during the fourth quarter. Great Lakes Retirement Inc. now owns 27,263 shares of the company’s stock valued at $1,356,000 after acquiring an additional 424 shares during the last quarter. Finally, Ritholtz Wealth Management increased its position in Sanofi by 1.3% during the fourth quarter. Ritholtz Wealth Management now owns 32,402 shares of the company’s stock valued at $1,611,000 after acquiring an additional 401 shares during the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on SNY shares. StockNews.com raised Sanofi from a “buy” rating to a “strong-buy” rating in a research note on Friday. Argus raised their price objective on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Price Performance

NASDAQ SNY traded down $0.70 during trading on Friday, hitting $52.40. 1,994,568 shares of the stock traded hands, compared to its average volume of 2,357,098. The company has a market capitalization of $132.72 billion, a P/E ratio of 26.33, a price-to-earnings-growth ratio of 1.65 and a beta of 0.59. The firm has a 50-day simple moving average of $49.21 and a 200-day simple moving average of $48.69. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. Sanofi has a 12-month low of $42.63 and a 12-month high of $55.72.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, April 25th. The company reported $0.96 EPS for the quarter, hitting analysts’ consensus estimates of $0.96. The firm had revenue of $11.36 billion during the quarter, compared to analysts’ expectations of $11.75 billion. Sanofi had a return on equity of 38.98% and a net margin of 9.60%. As a group, analysts predict that Sanofi will post 4.14 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.